Global News

Study: Biomarkers improve drug LOA exponentially

Tuesday, May 31, 2016

The Biotechnology Innovation Organization (BIO) released a study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade, “Clinical Development Success Rates 2006-2015” compares groups of diseases, drug modalities and other attributes to generate the most comprehensive analysis, to date, of biopharmaceutical R&D success.

[Read More]

Bioclinica launches OnPoint Direct

Tuesday, May 31, 2016

Bioclinica, a specialty clinical trials technology and services provider, has introduced OnPoint Direct, a Clinical Trial Management System (CTMS) geared toward mid-market biopharma and CROs. OnPoint Direct offers a cost-friendly pricing structure that empowers organizations to adopt a full-featured clinical trial management solution without the complex configuration, capital investment or perpetual licensing models customary of other systems.

[Read More]

Diverse populations—and transparent data—necessary for recruitment

Tuesday, May 31, 2016

The Pulse on Patient Recruitment by Ashley Tointon

Medicines affect various populations differently, so it is essential to have a diverse population when recruiting for clinical trials. Although specific patient recruitment tactics can be successfully deployed to reach certain sub-groups, there is a pervasive population disproportion in clinical trial participants. Such an understanding is the initial step to conquering the problem of minority recruitment. Once the gap is identified, the next and most difficult step is to implement actions designed to close the gap. 

[Read More]

Bicycle Therapeutics establishes U.S. operations

Thursday, May 26, 2016

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

[Read More]

Envigo appoints Scott Schulz Director of North American Operations

Thursday, May 26, 2016

Envigo has appointed Scott Schulz, MBA, to the post of director, North American (NA) Operations. In this role, Schulz will optimize operational performance and service delivery across the company’s North American based production locations for Research Models and Services (RMS). He will report directly to Michael Caulfield, president North American RMS at Envigo.

[Read More]